Prognostic Biomarker TP53 Mutations for Immune Checkpoint Blockade Therapy and Its Association With Tumor Microenvironment of Lung Adenocarcinoma

Immune checkpoint inhibitors (ICIs), is characterized by durable responses and improved survival in non-small cell lung cancer (NSCLC). However, there is a lack of predictive biomarkers to optimize the use of ICIs in cancers. The clinical benefit of patients with lung adenocarcinoma (LUAD) harboring...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Xinqing, Wang, Liqiang, Xie, Xiaohong, Qin, Yinyin, Xie, Zhanhong, Ouyang, Ming, Zhou, Chengzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710974/
https://www.ncbi.nlm.nih.gov/pubmed/33330629
http://dx.doi.org/10.3389/fmolb.2020.602328

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710974/
https://www.ncbi.nlm.nih.gov/pubmed/33330629
http://dx.doi.org/10.3389/fmolb.2020.602328

Ejemplares similares